Leveraging breast cancer screening to promote timely detection, diagnosis and treatment among women in sub-Saharan Africa: a scoping review protocol

Vida Nyagre Yakong, Agani Afaya, Robert Kaba Alhassan, Somin Sang, Solomon Mohammed Salia, Richard Adongo Afaya, Jebuni Fuseini Karim, Anthony Kuug, Daniels-Donkor Silas Selorm, Confidence Alorse Atakro, Renna Akokre, Peter Adataara, Martin Amogre Ayanore

ABSTRACT

Introduction Female breast cancer is now the most often diagnosed cancer in the world. Breast cancer screening aims to reduce mortalities related to cancer, and morbidity associated with advanced stages of the disease, through timely detection in asymptomatic women. This study aims to conduct a comprehensive assessment and evaluation of the evidence on the factors that influence the provision and uptake of breast cancer screening among women in sub-Saharan Africa (SSA).

Methods and analysis PubMed, Web of Science, EMBASE and the Cumulative Index to Nursing and Allied Health Literature including Google Scholar will be searched to identify published studies on barriers and facilitators to breast cancer screening from January 2010 to 2021. Two reviewers will independently assess the quality of all the included studies using the Mixed Methods Appraisal Tool version 2018. We envisage that this review will adduce evidence on common barriers and facilitators to breast cancer screening in SSA. Identifying these barriers and facilitators will help guide the initialisation of effective interventions that will improve breast cancer screening uptake among women in SSA. This review will also guide future research in developing, implementing and evaluating appropriate interventions tailored toward increasing breast cancer screening uptake.

Ethics and dissemination Ethics approval for this protocol is not required since it does not involve collecting data from human participants. The outcomes of this study will be published in a peer-reviewed journal.

INTRODUCTION

Globally, over 2.1 million women are affected yearly by the ravages of breast cancer, making it the most frequent cancer among women.5 According to statistics released by the International Agency for Research on Cancer (IARC) in December 2020, female breast cancer has overtaken lung cancer as the world’s most diagnosed cancer.2 Currently, breast cancer is considered a global public health problem due to its increasing incidence coupled with the high mortality rate among women both in developed and low-middle-income countries (LMICs).1,2 The IARC estimated 2.3 million new breast cancer cases in 2020 representing 11.7% of all cancer cases worldwide.2 Out of these cases, one in every eight cancer diagnoses is breast cancer. Also, the IARC estimated in 2020 that 685,000 women across the globe died of breast cancer. Between 1990 and 2017, it was estimated that the global breast cancer cases increased by about 123.14%.3 The GLOBOCAN cancer prediction tool estimates that by 2040 the global incidence of breast cancer cases is expected to increase more than 46%.4 It is estimated that by 2050 the prevalence of breast cancer cases in sub-Saharan Africa (SSA) will double.5 Currently in SSA, cancer control plans, prevention and strategies are weak; only a few cancer registries exist in most SSA countries with poorly structured cancer reporting systems.6,7 A recent study using a large prospective cohort

To cite: Yakong VN, Afaya A, Alhassan RK, et al. Leveraging breast cancer screening to promote timely detection, diagnosis and treatment among women in sub-Saharan Africa: a scoping review protocol. BMJ Open 2022;12:e058729. doi:10.1136/bmjopen-2021-058729

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2021-058729).

Received 26 October 2021
Accepted 04 May 2022

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to Dr Agani Afaya; agani@uhas.edu.gh

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This scoping review protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guideline.
⇒ The scoping review protocol is aimed to reduce the possibility of the duplication of this review, provide transparency to the methods and processes that will be employed, ensure bias reduction and allow peer review.
⇒ Despite a robust search strategy and the use of multiple electronic databases, potentially relevant studies might be missed.
of women with breast cancer among five countries in SSA revealed an alarming low 3-year survival rate, with near 40% in Nigeria, 45%–50% in Uganda and Zambia, and 56%–59% in South Africa and Namibia.8 Due to the lack of national cancer registries in SSA, the true burden of cancer incidence might probably be under-reported.9

It is evident that timely detection of breast cancer through screening is one of the breast cancer control strategies and this is one of the keys to meeting the global health goals including the Sustainable Development Goals.6 In developed countries, advances in breast cancer treatments, early presentation of symptoms before they become advanced cancer; more openness about cancer generally have all played a part in reducing the burden of breast cancer. Also, it is reported that the burden of cancer has been significantly reduced through well-coordinated screening programmes. In fact, in America, it is recommended that every woman at risk must undergo yearly breast cancer screening through mammography.10

A recent worldwide review and meta-analysis of cohort studies measuring the effect of mammography screening programmes on incidence-based breast cancer mortality revealed a 22% reduction in breast cancer mortality with an invitation to screening and a significant 33% reduction with actual attendance to screening.11 Several other studies have also reported screening via mammography reduces breast cancer-related deaths by 15%–20%.12–14 Though it has been proven that mammography is a reliable breast cancer screening method due to its ability to detect (some) symptoms early, finding it too early too many times has also shown to have some harmful effects and will incur more costs (physically, emotionally, psychologically, socially, financially), on women14 and also on the resources (financial and healthcare staff/professionals) of the health service in that country.

Clinical breast examination (CBE) is a relatively simple, easy and cost-effective method for the timely detection and diagnosis of breast cancer/tumours.15 A prospective cluster randomised controlled trial in Mumbai, India revealed that biennial CBE led to significant down-staging of breast cancer in all women including those younger than 50 and those aged 50 and older.16 The study revealed a non-significant 15% reduction in breast cancer mortality in the overall study population but a significant reduction of nearly 30% in mortality in women aged ≥50.16 Though mammography17 18 and CBE16 have their benefits, they also have some harmful effects on women, therefore, it is necessary that women are fully informed before they decide whether or not to undergo screening.19 20 Evidence from two large trials reported no beneficial effect of screening by breast self-examination (BSE) but rather reported increased harm in terms of increased numbers of benign lesions identified and an increased number of biopsies performed.21 Due to the above evidence, screening by BSE is not recommended.22 Therefore the current review will not include BSE.

Given the recent burden of breast cancer in SSA, a more comprehensive and detailed understanding of the barriers and facilitators is urgently required to prevent and plan interventions to reduce the burden of breast cancer. In our search in literature based on the review aim, we did not come across any existing published scoping review that has examined the barriers and facilitators of breast cancer screening among women in SSA.

Due to the lack of evidence, the main objective of this scoping review is to: (1) comprehensively review and assess evidence on the factors that influence the provision and uptake of breast screening among women in SSA. The secondary objectives are in two folds: (2) to highlight the barriers that influence breast cancer screening and (3) to identify the promoting factors (facilitators) of breast cancer screening uptake.

METHODS AND ANALYSIS
This scoping exercise is being undertaken using the Joana Briggs Institute (JBI) guideline recommendations.23 The review will also use the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) extension for Scoping Reviews.24

Patient and public involvement
This study will review published and grey literature; therefore, patients and the public were not involved in the development of this protocol.

Identification of research question
The main research question is: What factors influence breast cancer screening among women in SSA? Subquestions include (1) What are the factors that promote the provision and uptake of breast cancer screening among women in SSA? (2) What are the factors that hinder the provision and uptake of breast cancer screening among women in SSA? In accordance with JBI, a scoping review research question should cover the population, the concept and the context.25 With regard to our research question, the population is limited to women in SSA who have not been medically diagnosed with breast cancer. The concept is to identify factors influencing breast cancer screening (CBE/mammography), including barriers and facilitators. The context includes breast cancer screening services offered within hospitals, primary healthcare facilities and in the communities (as shown in table 1). Articles published between 2010 and 2021 will be included.

Search strategy
We will employ a comprehensive search strategy to identify various publications related to the aim of this review. The literature search will be conducted within the following electronic databases; PubMed, Web of Science, EMBASE and Cumulative Index to Nursing and Allied Health Literature (CINAHL via EBSCOhost). The search period for this review will be from January 2010 to 2021. To develop the preliminary search strategy, the reviewers will adopt the triple step approach to search for published evidence.26 The first step will involve an initial limited
search in PubMed and CINAHIL via EBSCOhost database. Subject terms (identified from relevant study titles and abstracts of articles) and free-text terms (identified from relevant study descriptions of articles) will be employed in the development of the preliminary search strategy. Step 2 will involve refining the second search terms which will be tailored to the various databases (PubMed, CINAHIL via EBSCOhost, Web of Science and EMBASE) including Google Scholar (see online supplemental appendix 1 for search strategies). In step 3, the citation list of the selected studies for the scoping review will be screened for additional relevant studies. The search findings will be in the English language and will be compiled by AA and SS.

Screening of studies
All the citations of the retrieved articles will be imported into Endnote X9 (V.1.19.6) reference manager for removal of duplicates, screening and storage. The titles and abstracts will be screened using the standard review process by reviewers. Full-text article screening will be done following title and abstract screening by two reviewers. After full-text screening, articles that will meet the inclusion criteria will be included in the data synthesis/analysis. Disagreements between the two independent reviewers on the full-text inclusion will be fully discussed and if not resolved a third review author will be consulted for further adjudication. We will provide a detailed written report giving reasons for the exclusion of articles from the final list of articles. Details of the selection process of the included and the excluded studies at various stages will be clearly shown in the PRISMA flow chart diagram for scoping reviews.

Selection criteria
Our search will focus on studies that assessed barriers and/or facilitators of breast cancer screening uptake among women in SSA. We will focus on articles published in the English language because the reviewers do not have the capacity to review articles written in other languages. These inclusive approaches will allow for the examination of current evidence on factors that would indicate the best way to improve breast cancer screening among women in SSA.

Inclusion criteria
This scoping review will include articles if they (1) involved women with no medical diagnosis of breast cancer as part of the study population, (2) assessed breast cancer screening (CBE/mammography) uptake among women, examining barriers and/or facilitators and were published between 2010 to 2021 and (3) were conducted in health facilities or service delivery in the community within SSA.

Exclusion criteria
The exclusion criteria will include studies that (1) screened for other cancers among women, (2) involved women with breast cancer history/survivors, (3) did not clearly state their study population to be women without breast cancer, and (4) were conducted outside the SSA region.

Types of studies included
This review will include all originally published articles in the form of quantitative, qualitative or mixed methods in nature. Quantitative studies will constitute non-experimental studies, including descriptive cross-sectional studies, observational studies and studies that use other quantitative methods. The qualitative studies will constitute focused group discussions, individual in-depth interviews and other forms of qualitative research designs that meet the criteria for qualitative studies. The mixed-methods studies will consist of qualitative and quantitative designs.

Data charting
Summary tables will be developed by the reviewers to extract key information required from the included articles. Two reviewer authors will independently extract data from the included studies. The extracted data will include the name of the first author, year of publication, country of study, study design, study aim, participants and sample size, type of breast cancer screening, and key findings (focusing on barriers and facilitators of breast cancer screening). The reviewer authors will reconcile the extracted information to make sure that the information is consistent with the originally published studies. If any part of the included study designs or conclusions is unclear to the review authors, they will consult one another.

Data synthesis and analysis
A convergent qualitative synthesis design will be employed, where results from qualitative, quantitative and mixed-method studies will be transformed into qualitative findings. Researchers will adopt a higher level of thematic approach to synthesise the data emerging from the literature. The summaries of the results will be thoroughly read and reread to gain meaning. Free line-by-line coding will be performed for each study to identify free
codes. Codes will be reviewed, and similar codes categorised to form descriptive themes. The descriptive themes will be assessed to generate meaning beyond the initial data leading to the development of new, interpretive analytical themes.

Assessment of methodological quality
The Mixed Methods Appraisal Tool\(^7^\) will be used for appraising and evaluating the qualitative, quantitative and mixed-methods studies. Two reviewers will independently review the articles and assign the quality rating. Discrepancies regarding the quality assessment of the articles included will be discussed among all the authors to resolve disagreements and agree on. There exist controversies as to whether studies that are appraised as poor quality should be excluded, as exclusion may lead to the loss of potentially relevant findings and increase bias.\(^28^\)\(^29^\) Consequently, the reviewers will not exclude any study if the study meets the inclusion criteria.

Data presentation
This scoping review will present the charted data in tables that align with the purpose of the study. Descriptive numerical summaries of the quantitative data will be provided where possible (especially the study’s characteristics and frequency counts for barriers and facilitators). Finally, these presentations will be accompanied by narrative explanations of important findings that explain how the findings address the review questions.

Ethics and dissemination
Ethical approval for this protocol is not required since it does not involve collecting data from human participants. To the best of our knowledge, this review will be the first to systematically map current literature available concerning barriers and facilitators to breast cancer screening among women in SSA. Therefore, this scoping review will be of interest to international researchers, oncology nurses, public health professionals and policymakers across SSA. The findings of this review will be published in a peer-reviewed journal and will also be presented in conferences and workshops to clinicians and public health professionals.

DISCUSSION
This review will systematically and comprehensively assess evidence on barriers and facilitators to breast cancer screening among women in SSA. The surge and high burden of breast cancer mortality in LMICs, especially in SSA are alarming.\(^2^\) Therefore, interventions to reduce the morbidity and mortality of breast cancer are required to ensure timely detection among asymptomatic women in the subregion. The significance of this review is to coalesce existing study findings on barriers and facilitators to breast cancer screening uptake to inform policy and aid to bridge the screening services in SSA. Though rigour is applied to this review protocol, likely limitations may eventuate due to resourcing considerations and the nature of the scoping review. First, this review will include only published articles in English which might exclude relevant evidence published in other languages. Second, authors may unintentionally omit relevant studies from this review, although extensive database and hand searches will be conducted. Nonetheless, this study will provide a comprehensive insight into the barriers and facilitators of breast cancer screening in SSA. The findings can also inform policy decision making to increase breast cancer screening within SSA countries. Publishing this scoping review protocol will help reduce the risk of bias by strengthening the clarity of the search strategy and reporting of the outcome.

Author affiliations
1Department of Preventive Health Nursing, School of Nursing and Midwifery, University for Development Studies, Tamale, Ghana
2College of Nursing, Yonsei University, Seodaemun-gu, Seoul, Republic of Korea
3Department of Nursing, School of Nursing and Midwifery, University of Health and Allied Sciences, Ho, Ghana
4Centre for Health Policy and Implementation Research. Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana
5Graduate School of Medical Sciences, Research Institute SHARE, University of Groningen, Groningen, the Netherlands
6Department of Midwifery and Women’s Health, School of Nursing and Midwifery, University for Development Studies, Tamale, Ghana
7Department of Nursing, Superior School of Health, University of Algarve, Campus de Gambelas, Ed. 5-8005-193, Faro Portugal, Portugal
8Department of Nursing, School of Health Sciences, University of Dundee, Scotland, UK
9Department of Nursing, Christian Service University College, Kumasi, Ghana
10Department of Nursing, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
11Department of Health Policy Planning and Management, School of Public Health, University of Health and Allied Sciences, Ho, Ghana

Contributors VNY, AA, SS and RAA developed the protocol with important intellectual content from SMS, JFK, RA, AK, D- OSS, CAA, RA, PA and MAA. AA, RKA, SS, PA and MAA developed the search strategies with consultation from a medical librarian. VNY, AA, RKA, SS, RA, SMS, JFK and MAA drafted and critically revised the manuscript for important intellectual content. SS, SMS, JFK, RKA, AK, D- OSS, CAA, RA, PA and MAA contributed to the revision of the manuscript for improvement. All authors read and approved the final version for publication.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is licensed under the terms of the licence.
properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**
Vida Nyagre Yakong http://orcid.org/0000-0001-8014-2989
Amani Afaya http://orcid.org/0000-0001-5271-3975
Richard Adongo Afaya http://orcid.org/0000-0003-4616-7642
Solomon Mohammed Salia http://orcid.org/0000-0002-9023-3240
Jebuni Fuselin Karim http://orcid.org/0000-0002-6841-9495
Confidence Alonso Atakro http://orcid.org/0000-0002-9944-8619
Martin Amogre Ayanore http://orcid.org/0000-0002-4095-3047

**REFERENCES**

1. World Health Organization. Breast cancer, 2020. Available: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/

2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–49.

3. Ji P, Gong Y, Jin M-L, et al. The burden and trends of breast cancer from 1990 to 2017 at the global, regional, and national levels: results from the global burden of disease study 2017. *Front Oncol* 2020;10:650.

4. Heer E, Harper A, Escandor N, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. *Lancet Glob Health* 2020;8:e1027–37.

5. Cumber SN, Nchani KN, Tsoka-Gwegevni JM. Breast cancer among women in sub-Saharan Africa: prevalence and a situational analysis. *South Afr J Gynaecol Oncol* 2017;9:35–7.

6. Idowu A, Olowookere SA, Olumide A, et al. Breast cancer awareness, knowledge and screening practice among women resident in an urban local government area of Oyo State, Nigeria. *J Cancer Policy* 2019;20:100179.

7. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–424.

8. McCormack V, McKenzie F, Foester M, et al. Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): a prospective cohort study. *Lancet Glob Health* 2020;8:e1203–12.

9. Black E, Richmond R. Improving early detection of breast cancer in sub-Saharan Africa: why mammography may not be the way forward. *Global Health* 2019;15:3.

10. Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin* 2016;66:95–114.

11. Dibden A, Offman J, Duffy SW, et al. Worldwide review and meta-analysis of cohort studies measuring the effect of mammography screening programmes on incidence-based breast cancer mortality. *Cancers* 2020;12:976. doi:10.3390/cancers12040976

12. Broders M, Moss S, Nyström L, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. *J Med Screen* 2012;19:14–25.

13. Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. *Ann Oncol* 2005;16:i553–62.

14. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. *Lancet* 2012;380:1778–86.

15. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening-viewpoint of the IARC Working Group. *N Engl J Med* 2015;372:2353–8.

16. Mittra I, Mishra GA, Dikshit RP, et al. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. *BMJ* 2021;372:n256.

17. Siu AL. U.S. Preventive Services Task Force. Screening for breast cancer. U.S. preventive services task force recommendation statement. *Ann Intern Med* 2016;164:279–96.

18. Ahn S, Wooster M, Valente C, et al. Impact of screening mammography on treatment in women diagnosed with breast cancer. *Ann Surg Oncol* 2018;25:2979–86.

19. Gøtzsche PC, Jørgensen KJ, Cochrane Breast Cancer Group. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews* 2013;156.

20. Seaman K, Dzidic PL, Castell E, et al. Subject positions in screening mammography and implications for informed choice. *Psychol Health Med* 2018;23:478–95.

21. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. *Cochrane Database Syst Rev* 2003;2.

22. Thornton H, Pillarisetti RR. ‘Breast awareness’ and ‘breast self-examination’ are not the same. What do these terms mean? Why are they confused? What can we do? *Eur J Cancer* 2008;44:2118–21. doi:10.1016/j.ejca.2008.08.015

23. Peters M, Godfrey C, McInerney P. The Joanna Briggs Institute reviewers’ manual 2015: methodology for JBI scoping reviews, 2015. Available: http://www.ncbi.nlm.nih.gov/pubmed/26134548

24. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169:467–73.

25. Peters MD, Godfrey C, McInerney P. Scoping reviews. *Joanna Briggs Institute Reviewer’s Manual* 2015;2017:1–24.

26. Pluye P, Hong QN. Combining the power of stories and the power of numbers: mixed methods research and mixed studies reviews. *Ann Rev Public Health* 2014;35:29–45.

27. Hong Q, Pluye P, Iresqeu S, et al. *Mixed methods appraisal tool (MMAT) version 2018: user guide*. Montreal: McGill University, 2018.

28. Majid U, Vanstone M. Appraising qualitative research for evidence syntheses: a compendium of quality appraisal tools. *Qual Health Res* 2018;28:2115–31.

29. Soilemezi D, Linceviciute S. Synthesizing qualitative research: reflections and lessons learnt by two new reviewers. *Int J Qual Method* 2018;17:1609406918786014.
### Appendix 1: Sample of search strategies

| Databases | No | Search terms                                                                                                                                                                                                 | Results                                                                                       |
|-----------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| PubMed    | 1  | ("Breast Neoplasms"[MeSH Terms] OR "Breast cancer"[All Fields] OR "Breast Neoplasia"[All Fields] OR "Breast Tumor"[All Fields]) AND (2010:2020[pdat])        |                                                                                               |
|           | 2  | ("Mammography"[MeSH Terms] OR "Breast Self-Examination"[MeSH Terms] OR "Clinical Breast Examination"[All Fields] OR "Early Detection of Cancer"[All Fields] OR "Mass Screening"[All Fields] OR "Breast cancer early detection"[All Fields] OR "Breast cancer screening"[All Fields] OR "Screening"[All Fields]) AND (2010:2020[pdat]) |                                                                                               |
|           | 3  | ("Africa"[MeSH Terms] OR "Africa South of the Sahara"[MeSH Terms] OR "Africa"[All Fields] OR "African"[All Fields] OR "Africans"[All Fields] OR "Sub-Saharan Africa"[All Fields] OR "Sub-Saharan African"[All Fields] OR "Central African Republic"[All Fields] OR "Chad"[All Fields] OR "Congo"[All Fields] OR "Democratic Republic of the Congo"[All Fields] OR "Equatorial Guinea"[All Fields] OR "Gabon"[All Fields] OR "Sao Tome and Principe"[All Fields] OR "Sao Tome"[All Fields] OR "Burundi"[All Fields] OR "Djibouti"[All Fields] OR "Eritrea"[All Fields] OR "Ethiopia"[All Fields] OR "Kenya"[All Fields] OR "Rwanda"[All Fields] OR "Somalia"[All Fields] OR "South Sudan"[All Fields] OR "Sudan"[All Fields] OR "Tanzania"[All Fields] OR "Uganda"[All Fields] OR "Angola"[All Fields] OR "Botswana"[All Fields] OR "Lesotho"[All Fields] OR "Malawi"[All Fields] OR "Mozambique"[All Fields] OR "Namibia"[All Fields] OR "South Africa"[All Fields] OR "Swaziland"[All Fields] OR "Eswatini"[All Fields] OR "Zambia"[All Fields] OR "Zimbabwe"[All Fields] OR "Benin"[All Fields] OR "Burkina Faso"[All Fields] OR "Cote d'Ivoire"[All Fields] OR "Ivory Coast"[All Fields] OR "Gambia"[All Fields] OR "Ghana"[All Fields] OR "Guinea"[All Fields] OR "Guinea-Bissau"[All Fields] OR "Liberia"[All Fields] OR "Mali"[All Fields] OR "Mauritania"[All Fields] OR "Niger"[All Fields] OR "Nigeria"[All Fields] OR "Senegal"[All Fields] OR "Sierra Leone"[All Fields] OR "Togo"[All Fields] OR "Madagascar"[All Fields]) AND (2010:2020[pdat]) |                                                                                               |
|           | 4  | 1 AND 2 AND 3                                                                                                                                                                                                  |                                                                                               |
| Web of science | 1  | TS=("Breast cancer" OR "Breast Neoplasia" OR "Breast Neoplasms" OR "Breast Tumor")                                                                                                                          |                                                                                               |
|           | 2  | TS=("Mammography" OR "Breast Self-Examination" OR "Clinical Breast Examination" OR "Early Detection of Cancer" OR "Mass Screening" OR "Breast cancer early detection" OR "Breast cancer screening" OR "Screening") |                                                                                               |
|           | 3  | TS=("Africa" OR "African" OR "Africans" OR "Sub-Saharan Africa" OR "sub-Saharan African" OR "Central African Republic" OR "Chad" OR "Congo" OR "Democratic Republic of the Congo" OR "Equatorial Guinea" OR "Gabon" OR "Sao |                                                                                               |
| CINAHL 4 | 1 AND 2 AND 3 |
|-----------|---------------|
| 1         | (MH "Breast cancer" OR "Breast Neoplasia" OR "Breast Neoplasms" OR "Breast Neoplasm" OR "Breast Tumor") |
| 2         | (MH "Early Detection of Cancer"[MESH] OR "Mass Screening"[MESH] OR "Breast cancer early detection" OR "Breast cancer screening" OR "Breast screening" OR "Cancer screening" OR "Early diagnosis of cancer" OR "Cancer early diagnosis" OR "Screen-and-treat" OR "Screening" OR "breast self-examination" OR "Clinical breast examination" OR "Breast examination" OR Mammogram OR Mammography) |
| 3         | (MH "Africa+" OR "Africa" OR "African" OR "Africans" OR "sub-Saharan Africa" OR "sub-Saharan African" OR "sub-Saharan Africans" OR "Cameroon" OR "Central African Republic" OR "Chad" OR "Congo" OR "Democratic Republic of the Congo" OR "Equatorial Guinea" OR "Gabon" OR "Sao Tome and Principe" OR "Sao Tome" OR "Burundi" OR "Djibouti" OR "Eritrea" OR "Ethiopia" OR "Kenya" OR "Rwanda" OR "Somalia" OR "South Sudan" OR "Sudan" OR "Tanzania" OR "Uganda" OR "Angola" OR "Botswana" OR "Lesotho" OR "Malawi" OR "Mozambique" OR "Namibia" OR "South Africa" OR "Swaziland" OR "Zambia" OR "Zimbabwe" OR "Benin" OR "Burkina Faso" OR "Cabo Verde" OR "Cote d’Ivoire" OR "Ivory Coast" OR "Gambia" OR "Ghana" OR "Guinea" OR "Guinea-Bissau" OR "Liberia" OR "Mali" OR "Mauritania" OR "Niger" OR "Nigeria" OR "Senegal" OR "Sierra Leone" OR "Togo" OR "Madagascar") |
| 4         | 1 AND 2 AND 3 |

| EMBASE 4 | 1 AND 2 AND 3 |
|-----------|---------------|
| 1         | 'breast cancer'/exp OR 'breast cancer' OR 'breast neoplasia' OR 'breast neoplasms'/exp OR 'breast neoplasms' OR 'breast neoplasm' OR 'breast tumor'/exp OR 'breast tumor' |
| 2         | 'early detection of cancer'/exp OR 'early detection of cancer' OR 'mass screening'/exp OR 'mass screening' OR 'breast cancer early detection' OR 'breast cancer screening' OR 'breast screening' OR 'cancer screening'/exp OR 'cancer screening' OR 'early diagnosis of cancer' OR 'breast self-examination'/exp OR 'breast self-examination' OR 'clinical breast examination'/exp OR 'clinical breast examination' OR 'breast examination'/exp OR 'breast examination' |
|   |   |
|---|---|
| 3 | 'africa'/exp OR 'africa' OR 'african'/exp OR 'african' OR 'africans'/exp OR 'africans' OR 'sub-saharan africa'/exp OR 'sub-saharan africa' OR 'sub-saharan african' OR 'sub-saharan africans' OR 'cameroon'/exp OR 'cameroon' OR 'central african republic'/exp OR 'central african republic' OR 'chad'/exp OR 'chad' OR 'congo'/exp OR 'congo' OR 'democratic republic of the congo'/exp OR 'democratic republic of the congo' OR 'equatorial guinea'/exp OR 'equatorial guinea' OR 'gabon'/exp OR 'gabon' OR 'sao tome and principe'/exp OR 'sao tome and principe' OR 'sao tome' OR 'burundi'/exp OR 'burundi' OR 'djibouti'/exp OR 'djibouti' OR 'eritrea'/exp OR 'eritrea' OR 'ethiopia'/exp OR 'ethiopia' OR 'kenya'/exp OR 'kenya' OR 'rwanda'/exp OR 'rwanda' OR 'somalia'/exp OR 'somalia' OR 'south sudan'/exp OR 'south sudan' OR 'sudan'/exp OR 'sudan' OR 'tanzania'/exp OR 'tanzania' OR 'uganda'/exp OR 'uganda' OR 'angola'/exp OR 'angola' OR 'botswana'/exp OR 'botswana' OR 'lesotho'/exp OR 'lesotho' OR 'malawi'/exp OR 'malawi' OR 'mozambique'/exp OR 'mozambique' OR 'namibia'/exp OR 'namibia' OR 'south africa'/exp OR 'south africa' OR 'swaziland'/exp OR 'swaziland' OR 'eswatini'/exp OR 'eswatini' OR 'zambia'/exp OR 'zambia' OR 'zimbabwe'/exp OR 'zimbabwe' OR 'benin'/exp OR 'benin' OR 'burkina faso'/exp OR 'burkina faso' OR 'cabo verde'/exp OR 'cabo verde' OR 'cote divoire' OR 'cote divoire' OR 'ivory coast'/exp OR 'ivory coast' OR 'gambia'/exp OR 'gambia' OR 'ghana'/exp OR 'ghana' OR 'guinea'/exp OR 'guinea' OR 'guinea-bissau'/exp OR 'guinea-bissau' OR 'liberia'/exp OR 'liberia' OR 'mali'/exp OR 'mali' OR 'mauritania'/exp OR 'mauritania' OR 'niger'/exp OR 'niger' OR 'nigeria'/exp OR 'nigeria' OR 'senegal'/exp OR 'senegal' OR 'sierra leone'/exp OR 'sierra leone' OR 'togo'/exp OR 'togo' OR 'madagascar'/exp OR 'madagascar' |
| 4 | 1 AND 2 AND 3 |
BMJ Change of Authorship Form

Please complete this form to request any authorship change(s) to your manuscript. This form should be completed in full by the Corresponding Author, who is responsible for obtaining the approval of all authors before submission. Any personal data supplied in this form will be processed in accordance with BMJ’s Privacy Notice for the purpose of recording the change(s) requested. Completed forms should be sent by email to the relevant Journal’s Editorial Office.

**PART A: Manuscript and basic information**

| Journal name: | BMJ Open |
|---------------|----------|
| Manuscript ID: | bmjopen-2021-058729 |
| Manuscript title: | Leveraging breast cancer screening to promote timely detection, diagnosis, and treatment of breast cancer among women in sub-Saharan Africa: a scoping review protocol |
| Named Corresponding Author: | Agani Afaya |
| Revision no: | bmjopen-2021-058729.R2 |

**PART B: Proposed authorship changes**

Please complete this section of the form to tell us about the changes you wish to implement to the authorship of your manuscript. To ensure the changes are compliant with BMJ’s authorship requirements please refer to BMJ’s authorship policy and the ICMJE Recommendations on authorship.

|   | Corresponding Author |
|---|----------------------|
| 1.1 | Do you wish to change the named Corresponding Author* |
| | ☑ No change – Please proceed to question 2 |
| | ☐ Yes – Please proceed to question 1.2 |
| *The Corresponding Author is the point of contact and will be required to liaise with BMJ’s Editorial Team in all matters relating to the publication of your manuscript. |
| 1.2 | Please confirm the name of the proposed new corresponding author: |
| 2 | Named authors |
| 2.1 | Do you wish to update the authorship OR the order |
| | ☑ No change – Please proceed to question 3 |
of authors named for your manuscript?  □ Yes – Please proceed to question 2.2

2.2 Please confirm the proposed new authorship list in the list below. Authors should be listed in the order in which it is now proposed they are shown on the manuscript.

| Author Full Name          | Author Affiliation                                                                 | Author Contact Email Address  |
|---------------------------|-----------------------------------------------------------------------------------|-------------------------------|
| 1. Vida Nyagre Yakong     | Department of Preventive Health Nursing, School of Nursing and Midwifery, University for Development Studies, Tamale, Ghana | vidayakong@yahoo.ca           |
| 2. Agani Afaya            | 1. College of Nursing, Yonsei University, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea  
2. Department of Nursing, School of Nursing and Midwifery, University of Health and Allied Sciences, Ho, Ghana | aagani@uhas.edu.gh            |
| 3. Robert Alhassan Kaba   | Centre for Health Policy and Implementation Research. Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana | ralhassan@uhas.edu.gh         |
| 4. Somin Sang             | College of Nursing, Yonsei University, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea | sangsomin@yuhs.ac             |
| 5 Solomon Mohammed Salia | Department of Nursing, School of Nursing and Midwifery, University of Health and Allied Sciences, Ho, Ghana | ssMohammed@uhas.edu.gh        |
| 6. Richard Adongo Afaya   | Department of midwifery and Women's Health, School of Nursing and Midwifery, University for Development Studies, Tamale, Ghana | arichard@uds.edu.gh           |
| 7. Jebuni Fuseini Karim   | Superior School of Health, University of Algarve, Campus de Gambelas, Ed. 5-8005-193 Faro-Portugal | jbfk135@gmail.com             |
| 8. Anthony Kuug           | Department of Nursing, School of Nursing and Midwifery, University of Health and Allied Sciences, Ho, Ghana | akuug@uhas.edu.gh             |
| 9. Silas Selorm Daniels-Donkor | Department of Nursing, School of Nursing and Midwifery, University of Health and Allied Sciences, Ho, Ghana | daniels-donkormc.daniels.selorm@gmail.com |
| 10. Confidence Alorse Atakro | Department of Nursing, Christian Service University College, Kumasi, Ghana | confidenceatakro@gmail.com    |
| 11. Renna Akokre          | Department of Nursing, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana | reezy.ra@gmail.com            |
| 12. Peter Adatara         | Department of Nursing, School of Nursing and Midwifery, University of Health and Allied Sciences, Ho, Ghana | padatara@uhas.edu.gh          |
| 13. Martin Amogre         | Department of Health Policy Planning and                                            | mayanore@uhas.edu.gh          |
| Acknowledgements |  |
|------------------|---|
| 3.1 Do you wish to update the acknowledgements? |  |
| ✗ No change – Please proceed to question 4 |  |
| ☐ Yes – Please proceed to question 3.2 |  |
| 3.2 Please confirm the required changes: |  |

| Author Contributions |  |
|----------------------|---|
| 4.1 Do you wish to update the contributions? |  |
| ✗ No change – Please proceed to question 5 |  |
| ☐ Yes – Please proceed to question 4.2 |  |
| 4.2 Please confirm the required changes: |  |

| Competing Interests |  |
|---------------------|---|
| 5.1 Have any new authors been added to the list of named authors for your manuscript? |  |
| ✗ No change – Please proceed to question 5.3 |  |
| ☐ Yes – Please proceed to question 5.2 |  |
| 5.2 Please confirm that each new author has completed the ICME COI disclosure form and a copy is/copies are available on request. |  |
| ☐ Yes, confirmed – Please proceed to question 5.3 |  |
| 5.3 Do you need to update the competing interests listed for any existing author? |  |
| ✗ No change – Please proceed to Part D |  |
| ☐ Yes – Please proceed to question 5.4 |  |
| 5.4 Please confirm any updated competing interests in the list below. For information and guidance please refer to BMJ’s Policy on Competing Interests. Please note that where no competing interests have been provided for any author, the default statement on the published article will be “None declared”. |  |
| Author Name | Competing Interest(s) |
|------------|-----------------------|
| 1          |                       |
| 2          |                       |
| 3          |                       |
| 4          |                       |
| 5          |                       |

Where there are more than 5 authors whose competing interests require updating please use the continuation sheet provided.

PART C: Reason for change(s)

Please confirm why the proposed changes specified in Part B above are required.

As the corresponding author, I confirm that the authors’ list presented above is in the right order. We did not add any author to the authors’ list. We only amended Confidence Alorse Atakro name. Therefore, the authors’ list as arranged above is the right order of authorship.

The authors do not have any competing interests.

PART D: Legal

1. This form is provided by BMJ Publishing Group Limited, (company registration number 03102371) whose registered office is at BMA House, Tavistock Square, London, WC1H 9JR, United Kingdom (BMJ).
2. Any personal data supplied in this form will be processed in accordance with BMJ’s Privacy Notice for the purpose of recording the change(s) requested.
3. All change(s) requested must comply in full with BMJ’s authorship policy and the ICMJE Recommendations on authorship. BMJ reserves the right to accept or refuse any change(s) requested in this form for any reason at BMJ’s full discretion.
4. To the fullest extent permitted by law, in no circumstances shall BMJ be liable to the Corresponding Author or any other named author, or to any party, for any direct, indirect, incidental or consequential losses or expenses arising from the change(s) requested in this form.
5. Nothing in this Part D seeks to exclude liability for death or personal injury caused by BMJ’s negligence or fraudulent misstatement. If BMJ has any liability in connection with the change(s) requested in this form, BMJ’s aggregate liability shall not exceed £10,000.
6. The Corresponding Author shall indemnify BMJ against any claims, costs, expenses, proceeding, awards and demands against BMJ by the Corresponding Author, any other named author, or any other party arising as a result of the change(s) requested in this form and any breach of the warranties provided in Part E.

PART E: Declaration

IMPORTANT NOTICE: Please ensure you have read Parts D and E carefully before signing this form. In signing this...
form you are confirming that the Declaration below is correct to the best of your knowledge and belief. If it later transpires that the statements below are incorrect or inaccurate, you could be liable for any resulting damage or losses sustained by BMJ.

**DECLARATION**

I confirm and warrant to BMJ that, to the best of my knowledge and belief:

- the information contained in this form is complete and accurate in all respects;

- a copy of this form has been provided to each existing author (including each author named in Part B), who have each approved the contents of this form (including any changes requested therein) prior to the submission of this form to BMJ;

- each author named in Parts B has consented to the storage and processing of their personal data contained in this form by BMJ in accordance with [BMJ’s Privacy Notice](#); and

- I am authorised to submit this form to BMJ on behalf of all existing authors (including each author named in Part B).

| Signed (Corresponding Author): | [Signature] |
|---------------------------------|------------|
| Print name:                     | Agani Afaya|
| Date:                           | 08-05-2022 |

*Completed forms should be sent to the Journal Editorial Office who will contact the Corresponding Author in due course to confirm whether the changes requested have been accepted or rejected.*
| Author Full Name | Author Affiliation | Author Contact Email Address |
|------------------|--------------------|-----------------------------|
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
|                  |                    |                             |
### CONTINUATION SHEET: PART C: Competing interest(s) change

| Author Full Name | Competing Interest(s) |
|------------------|-----------------------|
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |
|                  |                       |